Seeking Alpha

Barron's sees the biotech sector enjoying its strongest start to a new year in a decade,...

Barron's sees the biotech sector enjoying its strongest start to a new year in a decade, and this outperformance should continue for several reasons including P/E multiples and increasing M&A. The piece also discusses product ramp-ups at InterMune (ITMN), Human Genome Sciences (HGSI) and Regneron (REGN). (submitted by Bret Jensen)
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs